Dag Henrik Reikvam1, Malin Holm Meyer-Myklestad1,2, Marius Trøseid2,3, Birgitte Stiksrud1,2. 1. Department of Infectious Diseases, Oslo University Hospital. 2. Institute of Clinical Medicine, University of Oslo, Norway. 3. Research Institute of Internal Medicine, Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Abstract
PURPOSE OF REVIEW: To evaluate the current scientific basis for administering probiotics to people living with HIV (PLHIV) to alleviate chronic inflammation and subsequently improve their prognosis. RECENT FINDINGS: The gut microbiome is a potential contributing factor to low-grade inflammation in HIV infection, and there is a scientific rationale for attempting to attenuate inflammation by administering probiotics. Sixteen reports from clinical studies in antiretroviral therapy (ART)-treated PLHIV assessing inflammation after probiotic intervention have been identified; half of them randomized control trials (RCT). Some of the studies report improvement in some parameters of inflammation, but results are inconsistent. No studies report improvement of CD4 counts. None of the RCTs report improvements in any markers of inflammation when analyzed according to protocol. SUMMARY: Current scientific evidence does not support the use of probiotics to alleviate inflammation in HIV infection. The potential effect of probiotic intervention in ART-treated PLHIV with high risk for inflammation remains to be investigated.
PURPOSE OF REVIEW: To evaluate the current scientific basis for administering probiotics to people living with HIV (PLHIV) to alleviate chronic inflammation and subsequently improve their prognosis. RECENT FINDINGS: The gut microbiome is a potential contributing factor to low-grade inflammation in HIV infection, and there is a scientific rationale for attempting to attenuate inflammation by administering probiotics. Sixteen reports from clinical studies in antiretroviral therapy (ART)-treated PLHIV assessing inflammation after probiotic intervention have been identified; half of them randomized control trials (RCT). Some of the studies report improvement in some parameters of inflammation, but results are inconsistent. No studies report improvement of CD4 counts. None of the RCTs report improvements in any markers of inflammation when analyzed according to protocol. SUMMARY: Current scientific evidence does not support the use of probiotics to alleviate inflammation in HIV infection. The potential effect of probiotic intervention in ART-treated PLHIV with high risk for inflammation remains to be investigated.
Authors: Allison G Hays; Michael Schär; Patricia Barditch-Crovo; Shashwatee Bagchi; Gabriele Bonanno; Joseph Meyer; Yohannes Afework; Valerie Streeb; Samuel Stradley; Shannon Kelly; Nicole M Anders; Joseph B Margolick; Shenghan Lai; Gary Gerstenblith; Robert G Weiss Journal: AIDS Date: 2021-06-01 Impact factor: 4.632
Authors: Aroa Lopez-Santamarina; Alexandre Lamas; Alicia Del Carmen Mondragón; Alejandra Cardelle-Cobas; Patricia Regal; José Antonio Rodriguez-Avila; José Manuel Miranda; Carlos Manuel Franco; Alberto Cepeda Journal: Foods Date: 2021-01-09
Authors: Nichole R Klatt; Courtney Broedlow; Jessica M Osborn; Andrew T Gustin; Sandra Dross; Megan A O'Connor; Ernesto Coronado; Philip Barnette; Tiffany Hensley-McBain; Alexander S Zevin; Roshell Muir; Alexander Roederer; Solomon Wangari; Naoto Iwayama; Chul Y Ahrens; Jeremy Smedley; Cassandra Moats; Rebecca M Lynch; Elias K Haddad; Nancy L Haigwood; Deborah H Fuller; Jennifer A Manuzak Journal: NPJ Vaccines Date: 2021-03-11 Impact factor: 7.344
Authors: Talía Sainz; Laura Diaz; David Rojo; María Isabel Clemente; Coral Barbas; María José Gosalbes; Nuria Jimenez-Hernandez; Luis Escosa; Sara Guillen; José Tomás Ramos; María Ángeles Muñoz-Fernández; María Luisa Navarro; María José Mellado; Sergio Serrano-Villar Journal: Nutrients Date: 2022-02-26 Impact factor: 5.717